Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

An update on the constitutive androstane receptor (CAR).

Molnár F, Küblbeck J, Jyrkkärinne J, Prantner V, Honkakoski P.

Drug Metabol Drug Interact. 2013;28(2):79-93. doi: 10.1515/dmdi-2013-0009. Review.

PMID:
23729557
2.

Molecular dynamics simulations for human CAR inverse agonists.

Jyrkkärinne J, Küblbeck J, Pulkkinen J, Honkakoski P, Laatikainen R, Poso A, Laitinen T.

J Chem Inf Model. 2012 Feb 27;52(2):457-64. doi: 10.1021/ci200432k. Epub 2012 Jan 25.

PMID:
22233089
3.

New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists.

Küblbeck J, Jyrkkärinne J, Molnár F, Kuningas T, Patel J, Windshügel B, Nevalainen T, Laitinen T, Sippl W, Poso A, Honkakoski P.

Mol Pharm. 2011 Dec 5;8(6):2424-33. doi: 10.1021/mp2003658. Epub 2011 Nov 1.

PMID:
22044162
4.

Use of comprehensive screening methods to detect selective human CAR activators.

Küblbeck J, Laitinen T, Jyrkkärinne J, Rousu T, Tolonen A, Abel T, Kortelainen T, Uusitalo J, Korjamo T, Honkakoski P, Molnár F.

Biochem Pharmacol. 2011 Dec 15;82(12):1994-2007. doi: 10.1016/j.bcp.2011.08.027. Epub 2011 Sep 8.

PMID:
21924250
5.

Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship.

Jyrkkärinne J, Windshügel B, Rönkkö T, Tervo AJ, Küblbeck J, Lahtela-Kakkonen M, Sippl W, Poso A, Honkakoski P.

J Med Chem. 2008 Nov 27;51(22):7181-92. doi: 10.1021/jm800731b.

PMID:
18983136
6.

Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.

Repo S, Jyrkkärinne J, Pulkkinen JT, Laatikainen R, Honkakoski P, Johnson MS.

J Med Chem. 2008 Nov 27;51(22):7119-31. doi: 10.1021/jm800337r.

PMID:
18973326
7.

Discovery of substituted sulfonamides and thiazolidin-4-one derivatives as agonists of human constitutive androstane receptor.

Küblbeck J, Jyrkkärinne J, Poso A, Turpeinen M, Sippl W, Honkakoski P, Windshügel B.

Biochem Pharmacol. 2008 Nov 15;76(10):1288-97. doi: 10.1016/j.bcp.2008.08.014. Epub 2008 Aug 22.

PMID:
18786510
8.

Comparison of homology models and X-ray structures of the nuclear receptor CAR: assessing the structural basis of constitutive activity.

Windshügel B, Jyrkkärinne J, Vanamo J, Poso A, Honkakoski P, Sippl W.

J Mol Graph Model. 2007 Jan;25(5):644-57. Epub 2006 May 10.

PMID:
16831563
9.

Molecular dynamics simulations of the human CAR ligand-binding domain: deciphering the molecular basis for constitutive activity.

Windshügel B, Jyrkkärinne J, Poso A, Honkakoski P, Sippl W.

J Mol Model. 2005 Feb;11(1):69-79. Epub 2004 Dec 23.

PMID:
15616833
10.

Amino acids important for ligand specificity of the human constitutive androstane receptor.

Jyrkkärinne J, Windshügel B, Mäkinen J, Ylisirniö M, Peräkylä M, Poso A, Sippl W, Honkakoski P.

J Biol Chem. 2005 Feb 18;280(7):5960-71. Epub 2004 Nov 29.

11.

Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.

Jyrkkärinne J, Mäkinen J, Gynther J, Savolainen H, Poso A, Honkakoski P.

J Med Chem. 2003 Oct 23;46(22):4687-95.

PMID:
14561088
12.

Dual action of oestrogens on the mouse constitutive androstane receptor.

Mäkinen J, Reinisalo M, Niemi K, Viitala P, Jyrkkärinne J, Chung H, Pelkonen O, Honkakoski P.

Biochem J. 2003 Dec 1;376(Pt 2):465-72.

13.

Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors.

Mäkinen J, Frank C, Jyrkkärinne J, Gynther J, Carlberg C, Honkakoski P.

Mol Pharmacol. 2002 Aug;62(2):366-78.

PMID:
12130690

Supplemental Content

Loading ...
Support Center